Bright Minds Biosciences Inc.
DRUG | NASDAQ
$62.42
+$2.96 (+4.98%)
Sep 22, 2026, 11:46 AM ET · Market open
Fiscal Year Period Ending | FY 2025 Sep 29, 2025 | FY 2024 Sep 29, 2024 | FY 2023 Sep 29, 2023 | FY 2022 Sep 29, 2022 | FY 2021 Sep 29, 2021 | FY 2020 Sep 29, 2020 |
|---|---|---|---|---|---|---|
Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
Cost of Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
Gross Profit | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Income | -13.94M | -2.82M | -7.39M | -14.98M | -8.62M | -474.93K |
Interest Income | 1.52M | 30.13K | n/a | n/a | n/a | n/a |
Pretax Income | -12.23M | -2.8M | -7.37M | -14.96M | -8.65M | -480.38K |
Net Income | -12.23M | -2.8M | -7.37M | -14.96M | -8.65M | -480.38K |
Selling & General & Admin | 2.57M | 1.45M | 2.2M | 2.55M | 2.31M | 114.51K |
Research & Development | 11.08M | 1.18M | 5M | 12.18M | 6.31M | 354.85K |
Other Expenses | 287.65K | 197.19K | 186.65K | 243.08K | 0 | 5.45K |
Operating Expenses | 13.94M | 2.82M | 7.39M | 14.98M | 8.62M | 474.81K |
Interest Expense | n/a | n/a | n/a | n/a | n/a | n/a |
Selling & Marketing Expenses | 429.66K | 41.6K | 119.42K | 551.86K | 852.15K | 9.62K |
Cost & Expenses | 13.94M | 2.82M | 7.39M | 14.98M | 8.62M | 474.81K |
Income Tax Expense | n/a | n/a | n/a | n/a | n/a | n/a |
Shares Outstanding (Basic) | 6.88M | 4.31M | 3.72M | 2.47M | 1.79M | 1.28M |
Shares Outstanding (Diluted) | 6.88M | 4.31M | 3.72M | 2.47M | 1.79M | 1.28M |
EPS (Basic) | -1.78 | -0.65 | -1.98 | -6.15 | -4.74 | -0.38 |
EPS (Diluted) | -1.78 | -0.65 | -1.98 | -6.15 | -4.74 | -0.38 |
EBITDA | -12.15M | -2.73M | -7.3M | -14.96M | -27.64K | n/a |
EBIT | -12.23M | -2.8M | -7.37M | -14.96M | -8.65M | -474.93K |
Depreciation & Amortization | 76.87K | 73.36K | 72.45K | 6.04K | 8.62M | 474.93K |
Add to Watchlist
Select watchlists to add or remove DRUG